Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'

Ähnliche Einträge

• Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients
  von: Imafuku, Keisuke, et al.
  Veröffentlicht: (2017)
• Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration
  von: Imafuku, Keisuke, et al.
  Veröffentlicht: (2017)
• Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
  von: Imafuku, Keisuke, et al.
  Veröffentlicht: (2017)
• Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
  von: Bowyer, Samantha, et al.
  Veröffentlicht: (2017)
• Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
  von: Bowyer, S, et al.
  Veröffentlicht: (2016)